Global Demand Rises as Hospitals Adopt Advanced Imaging-based Biopsy Solutions
The global Image-guided Biopsy Market continues to gain momentum as healthcare systems worldwide embrace precision diagnostics and minimally invasive biopsy methods. According to industry data, the Image-guided Biopsy Market reached USD 4.01 billion in 2023 and is projected to climb to USD 6.98 billion by 2032, expanding at a CAGR of 6.35% from 2024 to 2032. The increasing need for accurate cancer detection and a strong shift toward safe, image-guided techniques contribute to the rapid adoption of advanced biopsy devices.
Growing rates of breast, lung, prostate, thyroid, and liver cancers have strengthened the demand for biopsies that deliver real-time accuracy while reducing complications. This has positioned the Image-guided Biopsy Market as a key pillar in modern oncology. Healthcare providers are investing heavily in ultrasound-guided, CT-guided, and MRI-assisted biopsy technologies to improve the reliability of tissue sampling. The expanding patient pool, combined with advancements in imaging tools and robotic assistance, is accelerating the market’s long-term growth.
A major factor influencing the Image-guided Biopsy Market is the clinical shift toward outpatient and ambulatory settings. With strong reimbursement support in many countries and the increasing availability of skilled radiologists and interventional specialists, hospitals and clinics remain the primary adopters of next-generation biopsy systems. Furthermore, ongoing technological innovations such as AI-enabled imaging, 3D navigation software, and automated biopsy guns are driving higher accuracy and faster diagnostics.
Get free Sample Report@ https://www.snsinsider.com/sample-request/2859
Core needle biopsy (CNB) continues to dominate the market due to its balance of precision and minimally invasive nature. Holding an estimated 52% share in 2023, CNB is widely recommended for diagnosing common cancers, supported by clinical guidelines that emphasize its accuracy. The integration of ultrasound and MRI guidance helps clinicians obtain high-quality samples while minimizing risk. Low cost, strong clinical reliability, and consistent histopathological results make CNB a preferred choice in diagnostic workflows.
Ultrasound-guided biopsy also held a major share of around 38% in 2023, driven by its accessibility, affordability, and real-time imaging capabilities. It has become the global standard for breast, thyroid, prostate, and soft tissue biopsies due to its non-radiation and repeatable nature. As healthcare facilities in emerging economies expand imaging capacity, ultrasound-guided procedures are expected to remain widely adopted. The segment is showing substantial growth in regions with limited access to MRI or CT.
Hospitals and clinics accounted for nearly 38% of total market activity in 2023. Their role as the central hubs for complex imaging procedures and patient care coordination ensures their continued leadership. The availability of specialized radiologists, advanced diagnostic infrastructure, and integrated oncology teams strengthens their position. Rising cancer prevalence also increases biopsy procedures performed in hospital settings. Favorable reimbursement and government investments further enable healthcare institutions to upgrade biopsy capabilities.
North America commanded approximately 41% of the market share in 2023. Strong research funding, early technology adoption, and high awareness of cancer screening programs underpin the region’s leadership. Investments by the National Cancer Institute (NCI) and quick regulatory approvals from agencies such as the FDA support innovation and adoption of cutting-edge biopsy solutions. The presence of established medical device manufacturers further boosts the market outlook.
Europe also held a substantial share thanks to its advanced healthcare systems and strong emphasis on disease screening and early diagnosis. Countries like Germany, France, and the United Kingdom have adopted state-of-the-art biopsy imaging technologies backed by favorable reimbursement policies. Leading universities and research institutes continue to contribute to advancements in minimally invasive biopsy tools and AI-supported diagnostics.
Asia Pacific is emerging as a high-potential growth region due to expanding healthcare access, rising cancer incidence, and rapid investments in medical imaging infrastructure. The shift toward modern diagnostic technologies in China, India, Japan, and South Korea is accelerating market penetration. Growing medical tourism and rising patient awareness further contribute to regional expansion.
Looking ahead, the Image-guided Biopsy Market is expected to experience continued advancements in imaging precision, robotics, AI-enabled automation, and portable biopsy systems. With a clear need for faster diagnosis and minimally invasive procedures, the market is positioned for steady growth through 2032. Strong focus on early cancer detection, patient comfort, and workflow efficiency will shape innovation and demand in the coming years.
FAQ
1. What is driving the growth of the Image-guided Biopsy Market?
Rising cancer rates, improvements in imaging accuracy, and increasing demand for minimally invasive diagnostic procedures are the main growth drivers.
2. Which imaging technology holds the largest market share?
Ultrasound-guided biopsy leads the market due to its accessibility, affordability, and real-time imaging benefits.
3. Which end user segment dominates the market?
Hospitals and clinics dominate due to strong imaging infrastructure and access to skilled specialists.
4. What regions are expected to show the fastest growth?
Asia Pacific is set for rapid expansion thanks to rising healthcare investments and cancer awareness.
5. What is the forecasted market size by 2032?
The global market is projected to reach USD 6.98 billion by 2032.
Other Trending Reports
Personalized Retail Nutrition And Wellness Market
IVD (In Vitro Diagnostics) Market
U.S. Pharmacy Benefit Management Market Growth
Functional Endoscopic Sinus Surgery Market Growth
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
